MCM
INO icon

Moore Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Moore Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-2,083
Closed -$207K – 402
2013
Q3 		$207K Buy
+2,083
New +$175K ﹤0.01% 342

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Moore Capital Management's INO Position: Q4 2013 in Review

Moore Capital Management sold out of Inovio Pharmaceuticals (INO) in Q4 2013, closing a stake of 2,083 shares — an estimated $207K sold.

Moore Capital Management first reported a position in INO in Q3 2013 and held it in 1 quarter. The position peaked at $207K in Q3 2013. 54 funds tracked by Wall St. Rank hold INO as of Q4 2013.

  • Moore Capital Management reported no remaining Inovio Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Moore Capital Management sold 2,083 Inovio Pharmaceuticals shares in Q4 2013, an estimated $207K.
  • Moore Capital Management first reported a position in Inovio Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Moore Capital Management's Inovio Pharmaceuticals position peaked at $207K in Q3 2013.
  • 54 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2013.

Based on Moore Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.